- Axsome Therapeutics, Inc. has reported past results for the second quarter and first half of 2026, with quarterly revenue of US$218.38 million and a net loss of US$51.31 million, and six‑month revenue of US$409.58 million and a net loss of US$115.86 million.
- While Axsome’s revenue increased compared with the prior year periods, its losses and loss per share also widened, underscoring the cost of expanding its central nervous system portfolio and commercialization efforts.
- We’ll now examine how Axsome’s higher revenue alongside a wider quarterly net loss shapes the existing investment narrative around its CNS portfolio.
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Axsome Therapeutics Investment Narrative Recap
To own Axsome, you need to believe its CNS portfolio, anchored by Auvelity, Sunosi and newer launches, can eventually offset today’s losses and heavy commercial spending. The latest results show solid top line expansion but a wider net loss, which keeps near term liquidity and execution as the key risk. The main short term catalyst, in my view, remains regulatory and commercial progress for late stage programs rather than this particular quarter, so the earnings print does not materially shift that focus.
Among recent announcements, the FDA acceptance of Axsome’s NDA for AXS‑12 in narcolepsy stands out. With a PDUFA date set for May 1, 2027, it highlights how future revenue diversity could ease Axsome’s current dependence on Auvelity and Sunosi at a time when gross to net discounts and rising SG&A are weighing on profitability. How efficiently Axsome advances AXS‑12 toward a potential launch will likely matter more for the longer term story than one quarter’s loss widening.
Yet, against that upside, investors should be aware that persistent net losses and a finite cash runway could still...
Read the full narrative on Axsome Therapeutics (it's free!)
Axsome Therapeutics’ narrative projects $2.5 billion revenue and $908.3 million earnings by 2029.
Uncover how Axsome Therapeutics' forecasts yield a $282.51 fair value, a 36% upside to its current price.
Exploring Other Perspectives
Some analysts were far more optimistic before this quarter, assuming revenue could reach about US$3.8 billion and earnings US$2.4 billion, which contrasts sharply with ongoing losses and shows how differently you and others might weigh Axsome’s still loss making profile versus its late stage pipeline.
Explore 7 other fair value estimates on Axsome Therapeutics - why the stock might be worth less than half the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Axsome Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.
Want Some Alternatives?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com